{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"14"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"17"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"Maximum grade of physician assessed adverse events graded and categorized using Common Toxicity Criteria for Adverse Events (CTCAE) version 4","groups":[{"description":"Everolimus 10 mg daily plus letrozole 2.5 mg PO daily in a 28 day cycle.","id":"OG000","title":"Everolimus and Letrozole"},{"description":"Tamoxifen 20 mg PO bid days 1-28 plus medroxyprogesterone acetate 200 mg PO days 8-14 and 22-28 repeating in a 28 day cycle.","id":"OG001","title":"Tamoxifen and Medroxyprogesterone Acetate"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and Treated Patients","reportingStatus":"POSTED","timeFrame":"Assessed throughout the treatment period and for 30 days after discontinuation of treatment. Treatment continues until progression of disease.","title":"Frequency and Severity of CTCAE (Common Toxicity Criteria for Adverse Events) Version 4","type":"SECONDARY","unitOfMeasure":"Participants"}